The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1611
ISSUE 1611
November 16, 2020
Empagliflozin (Jardiance) for Heart Failure
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
November 16, 2020 (Issue: 1611)
In a randomized, placebo-controlled trial, the
sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly)
reduced the composite risk of cardiovascular death
or hospitalization for worsening heart failure (HF)
in patients with heart failure with reduced ejection
fraction (HFrEF), whether or not they had type 2
diabetes. To date, empagliflozin has not been
approved by the FDA for such use. The SGLT2 inhibitor
dapagliflozin (Farxiga) was approved by the FDA for
this indication earlier this year.
... more
- M Packer et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383:1413.
- Dapagliflozin (Farxiga) – a new indication for heart failure. Med Lett Drugs Ther 2020; 62:102.
- JA Jarcho. More evidence for SGLT2 inhibitors in heart failure. N Engl J Med 2020; 383:1481.
- B Zinman et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117.
- JJV McMurray et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995.
- SD Wivott et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380:347.
- Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Med Lett Drugs Ther 2019; 61:26.
- CP Cannon et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383:1425.
- Drugs for chronic heart failure. Med Lett Drugs Ther 2019; 61:49.

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Empagliflozin (Jardiance) for Heart Failure
Article code: 1611b
Electronic, downloadable article - $45
Article code: 1611b
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian